ArticleCureus2025
Pan-Cancer Analysis Reveals Ribonuclease K (RNASEK) as a Potential Prognostic Biomarker in Pancreatic Cancer and a Diagnostic Indicator Across Multiple Human Cancers.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploratory Multi-Platform Bioinformatic Analysis of MEAK7 and Its Molecular, Survival, and Immune Associations in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is marked by rapid abnormal cell growth, leading to high mortality. The human Ribonuclease K (RNASEK) gene is involved in various cellular processes, such as viral infection, immune response, and maintaining cellular homeostasis. RNASEK, found in metazoans, contributes to tumor development, but the lack of systemic pan-cancer investigation into the diagnostic and prognostic function of RNASEK, epigenetic regulation, and interaction with the immune cell infiltration remains unclear. This study investigated RNASEK as a potential pan-cancer biomarker. METHODOLOGY: Public databases such as Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), and University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN) assessed RNASEK expression patterns. Gene Expression Omnibus (GEO) datasets validated these expressions. UALCAN examined RNASEK's expression differences, DNA methylation, and clinical features. TIMER analyzed SNHG8 expression about immune cell infiltration, while prognosis was evaluated through GEPIA, UALCAN, and Kaplan-Meier (KM) Plotter. cBioPortal reviewed the genetic alterations of RNASEK.
resultsOur study revealed a significant upregulation of RNASEK (
conclusionsIn conclusion, this study's pan-cancer analysis revealed that RNASEK could be a potential diagnostic biomarker in six cancer types, including BLCA, CHOL, ESCA, HNSC, LIHC, and THCA, and as a prognostic biomarker in PAAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.